Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 660 clinical trials
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

This pilot study is configured as a non-inferiority comparison of Performance Status 2 patients with Performance Status 0-1 patients, with the goal of demonstrating non-inferiority in terms of efficacy (progression-free survival, overall survival) and safety (rates of adverse events, quality of life) when treating Performance Status 2 patients with the …

pembrolizumab
small cell lung cancer
paclitaxel
dyspnea
neutrophil count
  • 0 views
  • 19 Feb, 2024
Trial with UK site 1

Trial with UK site 1

  • 0 views
  • 25 Jun, 2024
  • 1 location
Trial with UK site 2

Trial with UK site 1

  • 0 views
  • 25 Jun, 2024
  • 1 location
Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

This study compares gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for Hepatocellular Carcinoma (HCC) screening and surveillance in subjects with liver cirrhosis.

cirrhosis
hepatocellular carcinoma
carcinoma
  • 0 views
  • 19 Feb, 2024
Sandeep 03821 testing  

Testing by Sandeep 

Accepts healthy volunteers
cancer
Online studies
  • 0 views
  • 19 Feb, 2024
  • 1 location
RCT on Effect of Lymph Node Mapping by Indocyanine Green Via Submucosal or Subserosal Injection

The purpose of this study was to evaluate whether submucosal or subserous injection of indocyanine green during laparoscopic lymph node dissection of gastric cancer was different in tracing lymph nodes of gastric cancer. The patients with gastric adenocarcinoma (cT1-4a, Nmuramel +, M0) were studied.

gastric adenocarcinoma
papillary adenocarcinoma
signet ring cell carcinoma
lymphadenectomy
endoscopic biopsy
  • 0 views
  • 19 Feb, 2024
Infigratinib in Recurrent Glioblastoma Patients

Participants will be administered infigratinib prior to surgical resection of their tumor.

lipase
temozolomide
neutrophil count
contrast-enhanced magnetic resonance imaging
FGFR1
  • 0 views
  • 19 Feb, 2024
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

The primary hypothesis is that pembrolizumab + lenvatinib is superior to SOC chemotherapy with respect to ORR per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review.

antihypertensive agents
mk-3475
capecitabine
carcinoma
monoclonal antibody therapy
  • 0 views
  • 19 Feb, 2024
Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC)

This would be a phase II prospective single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) non-keratinizing nasopharyngeal carcinoma (NPC).

bintrafusp alfa
adjuvant therapy
neutrophil count
secondary malignant neoplasm of liver
measurable disease
  • 0 views
  • 19 Feb, 2024
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

This is the first phase II randomized clinical trial of concurrent chemoradiotherapy with or without EGFR blocker Nimotuzumab for high risk advanced nasopharyngeal carcinoma(NPC) , determining whether concurrent chemoradiotherapy(CCRT) combined with nimotuzumab can improve the survival rate of high-risk patients and may provide new evidence for individualized comprehensive treatment of …

EGFR
egfr blocker
concurrent radiochemotherapy
nasopharyngeal carcinoma
chemoradiotherapy
  • 4 views
  • 19 Feb, 2024